CARE: Centro de Alergia y Enfermedades Respiratorias

Buenos Aires C1414AIF

0 studies enrolling now · 6 studies all time

What they study most

Dermatitis, Atopic, Obesity, Overweight, Severe Asthma, Type 2 Diabetes

Studies at this site

• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) — Running, not enrolling
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) — Completed
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis — Stopped early